Correction to Lancet Oncol 2016; 17: 484–95 (The Lancet Oncology (2016) 17(4) (484–495), (S1470204515005811), (10.1016/S1470-2045(15)00581-1));Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

The Lancet Oncology

Volumn 17, Issue 4, 2016, Pages 484-495

  Thompson, Eric M ^a,c   Hielscher, Thomas ^e   Bouffet, Eric ^a   Remke, Marc ^g   Luu, Betty ^a   Gururangan, Sridharan ^d   McLendon, Roger E ^c   Bigner, Darell D ^c,d   Lipp, Eric S ^c   Perreault, Sebastien ^h   Cho, Yoon Jae ⁱ   Grant, Gerald ^i,j   Kim, Seung Ki ^k   Lee, Ji Yeoun ^k   Rao, Amulya A Nageswara ^l   Giannini, Caterina ^l   Li, Kay Ka Wai ^m   Ng, Ho Keung ^m   Yao, Yu ⁿ   Kumabe, Toshihiro ^o   Tominaga, Teiji ^p   Grajkowska, Wieslawa A ^q   Perek Polnik, Marta ^q   Low, David C Y ^r   Seow, Wan Tew ^r   Chang, Kenneth T E ^r   Mora, Jaume ^s   Pollack, Ian F ^t   Hamilton, Ronald L ^t   Leary, Sarah ^u   Moore, Andrew S ^v,w   Ingram, Wendy J ^v   Hallahan, Andrew R ^v,w   Jouvet, Anne ^x   Fèvre Montange, Michelle ^x   Vasiljevic, Alexandre ^y,z   Faure Conter, Cecile ^aa   Shofuda, Tomoko ^ab   Kagawa, Naoki ^ac   Hashimoto, Naoya ^ac   Jabado, Nada ^ad   Weil, Alexander G ^ad   Gayden, Tenzin ^ad   Wataya, Takafumi ^ae   Shalaby, Tarek ^af   Grotzer, Michael ^af   Zitterbart, Karel ^ag   Sterba, Jaroslav ^ag   Kren, Leos ^ah   Hortobágyi, Tibor ^ai   Klekner, Almos ^ai   László, Bognár ^ai   Pócza, Tímea ^aj   Hauser, Peter ^aj   Schüller, Ulrich ^ak   Jung, Shin ^al   Jang, Woo Youl ^al   French, Pim J ^am   Kros, Johan M ^am   van Veelen, Marie Lise C ^am   Massimi, Luca ^an   Leonard, Jeffrey R ^ao   Rubin, Joshua B ^ao   Vibhakar, Rajeev ^ap   Chambless, Lola B ^aq   Cooper, Michael K ^aq   Thompson, Reid C ^aq   Faria, Claudia C ^ar   Carvalho, Alice ^as   Nunes, Sofia ^at   Pimentel, José ^ar   Fan, Xing ^au   Muraszko, Karin M ^au   López Aguilar, Enrique ^av   Lyden, David ^aw   Garzia, Livia ^a   Shih, David J H ^a,b   Kijima, Noriyuki ^a   Schneider, Christian ^a   Adamski, Jennifer ^a   Northcott, Paul A ^e   Kool, Marcel ^e   Jones, David T W ^e   Chan, Jennifer A ^ax   Nikolic, Ana ^ax   Garre, Maria Luisa ^ay   Van Meir, Erwin G ^az   Osuka, Satoru ^az   Olson, Jeffrey J ^az   Jahangiri, Arman ^ba   Castro, Brandyn A ^ba   Gupta, Nalin ^ba   Weiss, William A ^ba,bb   Moxon Emre, Iska ^a   Mabbott, Donald J ^a   Lassaletta, Alvaro ^a   Hawkins, Cynthia E ^a   Tabori, Uri ^a   Drake, James ^a   Kulkarni, Abhaya ^a   Dirks, Peter ^a   Rutka, James T ^a,b   Korshunov, Andrey ^e   Pfister, Stefan M ^e,f   Packer, Roger J ^bc   Ramaswamy, Vijay ^a,b   Taylor, Michael D ^a,b   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE CANCER INSTITUTE   (United States)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^h UNIVERSITY OF MONTREAL   (Canada)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^k Seoul National University Children's Hospital   (South Korea)

^l MAYO CLINIC   (United States)

^m CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁿ FUDAN UNIVERSITY   (China)

^o KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^q CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^r KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^s HOSPITAL SANT JOAN DE DÉU   (Spain)

^t UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^u SEATTLE CHILDREN S HOSPITAL   (United States)

^v UNIVERSITY OF QUEENSLAND   (Australia)

^w LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^x UNIVERSITÉ DE LYON   (France)

^y HOSPICES CIVILS DE LYON   (France)

^z LYON NEUROSCIENCE RESEARCH CENTER   (France)

^aa Institute of Pediatric Hematology and Oncology   (France)

^ab OSAKA NATIONAL HOSPITAL   (Japan)

^ac OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^ad MCGILL UNIVERSITY   (Canada)

^ae SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^af UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^ag MASARYK UNIVERSITY   (Czech Republic)

^ah UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^ai UNIVERSITY OF DEBRECEN   (Hungary)

^aj SEMMELWEIS UNIVERSITY   (Hungary)

^ak UNIVERSITY OF MUNICH   (Germany)

^al Chonnam National University   (South Korea)

^am ERASMUS MEDICAL CENTER   (Netherlands)

^an CATHOLIC UNIVERSITY   (Italy)

^ao WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ap University of Colorado Denver and Children s Hospital Colorado   (United States)

^aq VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^ar HOSPITAL DE SANTA MARIA   (Portugal)

^as CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^at INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^au UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^av INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^aw WEILL CORNELL MEDICAL COLLEGE   (United States)

^ax UNIVERSITY OF CALGARY   (Canada)

^ay G GASLINI INSTITUTE   (Italy)

^az EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ba UNIVERSITY OF CALIFORNIA   (United States)

^bb UNIVERSITY OF CALIFORNIA   (United States)

^bc CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER TISSUE; CHILD; FEMALE; GENE EXPRESSION PROFILING; GEOGRAPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; ADULT; BRAIN NEOPLASMS; CANADA; CLASSIFICATION; DISEASE COURSE; DISEASE FREE SURVIVAL; GENETICS; INFANT; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRESCHOOL CHILD;

ADULT; BRAIN NEOPLASMS; CANADA; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; MEDULLOBLASTOMA; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84960370658     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(22)00006-7     Document Type: Erratum

References (41)

1. 1 Albright, AL, Wisoff, JH, Zeltzer, PM, Boyett, JM, Rorke, LB, Stanley, P, Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery 38 (1996), 265–271.
2. 2 Zeltzer, PM, Boyett, JM, Finlay, JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17 (1999), 832–845.
3. 3 Gajjar, A, Chintagumpala, M, Ashley, D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7 (2006), 813–820.
4. 4 Ramaswamy, V, Northcott, PA, Taylor, MD, FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genet 204 (2011), 577–588.
5. 5 Packer, RJ, Gajjar, A, Vezina, G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24 (2006), 4202–4208.
6. 6 Brasme, JF, Grill, J, Doz, F, et al. Long time to diagnosis of medulloblastoma in children is not associated with decreased survival or with worse neurological outcome. PLoS One, 7, 2012, e33415.
7. 7 Rutkowski, S, von Hoff, K, Emser, A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 28 (2010), 4961–4968.
8. 8 Packer, RJ, Boyett, JM, Janss, AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 19 (2001), 480–487.
9. 9 Johnston, DL, Keene, D, Bartels, U, et al. Medulloblastoma in children under the age of three years: a retrospective Canadian review. J Neurooncol 94 (2009), 51–56.
10. 10 Akyüz, C, Varan, A, Küpeli, S, et al. Medulloblastoma in children: a 32-year experience from a single institution. J Neurooncol 90 (2008), 99–103.
11. 11 Evans, AE, Jenkin, RD, Sposto, R, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72 (1990), 572–582.
12. 12 Stavrou, T, Bromley, CM, Nicholson, HS, et al. Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 23 (2001), 431–436.
13. 13 Grill, J, Sainte-Rose, C, Jouvet, A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 6 (2005), 573–580.
14. 14 Tait, DM, Thornton-Jones, H, Bloom, HJ, Lemerle, J, Morris-Jones, P, Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26 (1990), 464–469.
15. 15 Tarbell, NJ, Friedman, H, Polkinghorn, WR, et al. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol 31 (2013), 2936–2941.
16. 16 Albright, AL, Sposto, R, Holmes, E, et al. Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery 47 (2000), 879–885.
17. 17 Cochrane, DD, Gustavsson, B, Poskitt, KP, Steinbok, P, Kestle, JR, The surgical and natural morbidity of aggressive resection for posterior fossa tumors in childhood. Pediatr Neurosurg 20 (1994), 19–29.
18. 18 Korah, MP, Esiashvili, N, Mazewski, CM, et al. Incidence, risks, and sequelae of posterior fossa syndrome in pediatric medulloblastoma. Int J Radiat Oncol Biol Phys 77 (2010), 106–112.
19. 19 Robertson, PL, Muraszko, KM, Holmes, EJ, et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg 105:6 suppl (2006), 444–451.
20. 20 Levisohn, L, Cronin-Golomb, A, Schmahmann, JD, Neuropsychological consequences of cerebellar tumour resection in children: cerebellar cognitive affective syndrome in a paediatric population. Brain 123 (2000), 1041–1050.
21. 21 Gajjar, A, Sanford, RA, Bhargava, R, et al. Medulloblastoma with brain stem involvement: the impact of gross total resection on outcome. Pediatr Neurosurg 25 (1996), 182–187.
22. 22 Pollack, IF, Polinko, P, Albright, AL, Towbin, R, Fitz, C, Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Neurosurgery 37 (1995), 885–893.
23. 23 Kool, M, Korshunov, A, Remke, M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123 (2012), 473–484.
24. 24 Taylor, MD, Northcott, PA, Korshunov, A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123 (2012), 465–472.
25. 25 Thompson, MC, Fuller, C, Hogg, TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24 (2006), 1924–1931.
26. 26 Ramaswamy, V, Remke, M, Shih, D, et al. Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. Pediatr Blood Cancer 61 (2014), 1190–1194.
27. 27 Northcott, PA, Jones, DT, Kool, M, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer 12 (2012), 818–834.
28. 28 Northcott, PA, Dubuc, AM, Pfister, S, Taylor, MD, Molecular subgroups of medulloblastoma. Expert Rev of Neurother 12 (2012), 871–884.
29. 29 Northcott, PA, Korshunov, A, Pfister, SM, Taylor, MD, The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 8 (2012), 340–351.
30. 30 Northcott, PA, Korshunov, A, Witt, H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29 (2011), 1408–1414.
31. 31 Dubuc, AM, Remke, M, Korshunov, A, et al. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol 125 (2013), 373–384.
32. 32 Shih, DJ, Northcott, PA, Remke, M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 32 (2014), 886–896.
33. 33 Northcott, PA, Shih, DJ, Remke, M, et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 123 (2012), 615–626.
34. 34 Ramaswamy, V, Remke, M, Bouffet, E, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol 14 (2013), 1200–1207.
35. 35 Harrell, FE, Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis, 2011, Springer Heidelberg, Heidelberg.
36. 36 Pietsch, T, Schmidt, R, Remke, M, et al. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol 128 (2014), 137–149.
37. 37 Ramaswamy, V, Remke, M, Adamski, J, et al. Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. Neuro Oncol, 2015, 10.1093/neuonc/nou357 published online Jan 20.
38. 38 Perreault, S, Ramaswamy, V, Achrol, AS, et al. MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 35 (2014), 1263–1269.
39. 39 Lannering, B, Rutkowski, S, Doz, F, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30 (2012), 3187–3193.
40. 40 Moxon-Emre, I, Bouffet, E, Taylor, MD, et al. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. J Clin Oncol 32 (2014), 1760–1768.
41. 41 Garrè, ML, Cama, A, Bagnasco, F, et al. Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome—a new clinical perspective. Clin Cancer Res 15 (2009), 2463–2471.